UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Remaining Useful Life Estimation Considering Prior Accelerated Degradation Data and Bayesian Inference for Multi-Stress Operating Conditions

International journal of mathematical, engineering and management sciences, 2021-02, Vol.6 (1), p.103-117

2021

Volltextzugriff (PDF)

Remaining useful life prediction using the similarity-based integrations of multi-sensors data

Quality engineering, 2024-01, Vol.36 (1), p.36-53

2024

Volltextzugriff (PDF)

Reliability Analysis of Interdependent Stochastic-Flow Networks

2024 Annual Reliability and Maintainability Symposium (RAMS), 2024, p.1-6

2024

Volltextzugriff (PDF)

Advancing scaffold porosity through a machine learning framework in extrusion based 3D bioprinting

Frontiers in materials, 2024-02, Vol.10

2024

Volltextzugriff (PDF)

Factorial Design of Experiment Method to Characterize Bioprinting Process Parameters to Obtain the Targeted Scaffold Porosity

3D printing and additive manufacturing, 2024-10, Vol.11 (5), p.e1899-e1908

2024

Volltextzugriff (PDF)

Modulating rheological characteristics of bio-ink with component weight and shear rate for enhanced bioprinted scaffold fidelity

Bioprinting (Amsterdam, Netherlands), 2024-04, Vol.38, p.e00332, Article e00332

2024

Volltextzugriff (PDF)

Microbial diversity and community composition of caecal microbiota in commercial and indigenous Indian chickens determined using 16s rDNA amplicon sequencing

Microbiome, 2018-06, Vol.6 (1), p.115-115, Article 115

2018

Volltextzugriff (PDF)

Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

Annals of oncology, 2018-10, Vol.29, p.viii714-viii714

2018

Volltextzugriff (PDF)

Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.4040-4040

2020

Volltextzugriff (PDF)

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.3550-3550

2023

Volltextzugriff (PDF)

Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

The New England journal of medicine, 2024-10, Vol.391 (16), p.1486-1498

2024

Volltextzugriff (PDF)

Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update

Journal of clinical oncology, 2021-01, Vol.39 (3_suppl), p.58-58

2021

Volltextzugriff (PDF)

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update

Journal of clinical oncology, 2020-02, Vol.38 (4_suppl), p.11-11

2020

Volltextzugriff (PDF)

LBA18_PRDurable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.3521-3521

2019

Volltextzugriff (PDF)

1 – 15 von 15

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(14)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(14)
Tagungsberichte
(1)

Sprache

Englisch
(15)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(7)
Technology
(5)
Engineering
(4)
3d Bioprinting
(3)
Engineering, Multidisciplinary
(2)
Life Sciences & Biomedicine
(2)
Materials Science
(2)
Materials Science, Multidisciplinary
(2)
Mathematics
(2)
Physical Sciences
(2)
Remaining Useful Life
(2)
Shape Fidelity
(2)
Useful Life
(2)
16s Rrna Gene
(1)
Accelerated Degradation Test
(1)
Amplicon Sequencing
(1)
Analysis
(1)
Animals
(1)
Antitumor Activity
(1)
Artificial Intelligence
(1)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Remaining Useful Life Estimation Considering Prior Accelerated Degradation Data and Bayesian Inference for Multi-Stress Operating Conditions

Remaining useful life prediction using the similarity-based integrations of multi-sensors data

Reliability Analysis of Interdependent Stochastic-Flow Networks

Advancing scaffold porosity through a machine learning framework in extrusion based 3D bioprinting

Factorial Design of Experiment Method to Characterize Bioprinting Process Parameters to Obtain the Targeted Scaffold Porosity

Modulating rheological characteristics of bio-ink with component weight and shear rate for enhanced bioprinted scaffold fidelity

Microbial diversity and community composition of caecal microbiota in commercial and indigenous Indian chickens determined using 16s rDNA amplicon sequencing

Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update

First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in patients (pts) with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): 64-month (mo) follow-up from CheckMate 142

Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

Subgroup analyses of patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) treated with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line (1L) therapy:Two-year clinical update

Nivolumab plus low-dose ipilimumab as first-line therapy in microsatellite instability-high/DNA mismatch repair deficient metastatic colorectal cancer: Clinical update

LBA18_PRDurable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC)

Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update

Suchergebnisse filtern